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Introduction
Fibrillin microfi  brils of the ECM, which associate with elastic 
fi  bers, are implicated in the regulation of TGFβ in large latent 
complexes (LLCs; for review see Ramirez et al., 2004; Kielty, 
2006). Fibrillin-1 is a multidomain cysteine-rich glycoprotein 
containing 43 calcium-binding EGF (cbEGF)–like domains 
and 78 cysteine-containing TB motifs (Pereira et al., 1993). 
  Fibrillin-1 mutations cause the heritable disorder Marfan syn-
drome (MFS) with severe cardiovascular, skeletal, ocular, and 
lung manifestations (for review see Robinson et al., 2006).
Enhanced TGFβ signaling is a major contributor to the 
pathology of MFS. A model has been proposed in which fi  brillin-1 
mutations perturb the normal microfi  bril regulation of latent 
TGFβ and, thereby, contribute to MFS pathogenesis (for review 
see Dietz et al., 2005). The clinically overlapping conditions, 
Loeys-Dietz aortic aneurysm syndrome, familial thoracic aortic 
aneurysms and dissections, and marfanoid craniosynostoses are 
also caused by enhanced TGFβ signaling but, in these cases, are 
caused by cytoplasmic kinase mutations in TGFβ   receptor 
(TGFβR) I or II (Mizuguchi et al., 2004; Loeys et al., 2005, 
2006; Ades et al., 2006; Matyas et al., 2006; Singh et al., 2006). 
Mouse MFS models have revealed that enhanced TGFβ activity 
in fi  brillin-1 haploinsuffi  cient mice leads to primary develop-
mental failures, including distal alveolar septation (Neptune 
et al., 2003), and, in heterozygous mutant mice, leads to mitral 
valve defects (Ng et al., 2004). Haploinsuffi  ciency  triggers 
  secondary cellular events that result in intimal hyperplasia and 
adventitial infl  ammation with TGFβ involvement as well as 
aortic failure (for review see Dietz et al., 2005). Losartan, an 
angiotensin II blocker that lowers blood pressure and leads to 
the clinically relevant attenuation of TGFβ signaling, prevented 
aortic aneurysm in a mouse MFS model (Habashi et al., 2006). 
Tight-skin mice have enhanced TGFβ activity and sclerosis as 
a result of an internal fi  brillin-1 duplication and a larger than nor-
mal secreted protein (Siracusa et al., 1996; Menon et al., 2006).
TGFβ is secreted from cells as a dimeric small latent 
complex (SLC) comprising noncovalently associated latency-
associated propeptide (LAP) and active TGFβ and/or as a large 
LLC comprising SLC bound covalently to a latent TGFβ-binding 
protein (LTBP) through a TB motif (for reviews see Annes et al., 
2003; Hyytiäinen et al., 2004). Only LTBP-1 and -3 bind TGFβ 
strongly. It has been proposed that by interacting with LLC, 
 fi brillin microfi  brils may act as a growth factor highway in 
  tissues (for review see Ramirez et al., 2004). LTBPs are struc-
turally related to fi  brillins (for review see Sinha et al., 1998). 
LTBP-1 but not LTBP-3 can bind in vitro to fi  brillin-1 (Isogai 
et al., 2003). This interaction involves three C-terminal domains 
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e have discovered that ﬁ  brillin-1, which forms 
extracellular microﬁ   brils, can regulate the 
bioavailability of transforming growth factor 
(TGF) β1, a powerful cytokine that modulates cell survival 
and phenotype. Altered TGFβ signaling is a major con-
tributor to the pathology of Marfan syndrome (MFS) and 
related diseases. In the presence of cell layer extracellular 
matrix, a ﬁ  brillin-1 sequence encoded by exons 44–49 
releases endogenous TGFβ1, thereby stimulating TGFβ 
receptor–mediated Smad2 signaling. This altered TGFβ1 
bioavailability does not require intact cells, proteolysis, or 
the altered expression of TGFβ1 or its receptors. Mass 
spectrometry revealed that a ﬁ  brillin-1 fragment containing 
the TGFβ1-releasing sequence speciﬁ  cally associates with 
full-length ﬁ  brillin-1 in cell layers. Solid-phase and BIAcore 
binding studies showed that this fragment interacts strongly 
and speciﬁ  cally with N-terminal ﬁ  brillin-1, thereby inhibiting 
the association of C-terminal latent TGFβ-binding pro-
tein 1 (a component of the large latent complex [LLC]) with 
N-terminal ﬁ  brillin-1. By releasing LLC from microﬁ  brils, 
the ﬁ  brillin-1 sequence encoded by exons 44–49 can con-
tribute to MFS and related diseases.
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of LTBP-1 and four N-terminal domains of fi  brillin-1. LTBP-1 
is an associated but not an integral component of microfi  brils 
(Isogai et al., 2003; Cain et al., 2006), and it colocalizes with 
 fi brillin microfi  brils in some tissues (Dallas et al., 2000; Isogai 
et al., 2003). The prodomain of another TGFβ superfamily 
member, BMP-7, can bind an N-terminal fi  brillin-1 fragment in 
vitro (Gregory et al., 2005).
Activation of TGFβ, a potent growth factor that regulates 
cell proliferation, migration, differentiation, and survival, is nor-
mally tightly regulated. However, physiological activation mech-
anisms leading to receptor signaling are incompletely  understood. 
They may involve LTBP-1–mediated proteolytic release, 
thrombospondin-1 (TSP-1) competition with SLC,   integrin pre-
sentation, pH changes, and reactive oxygen species (for reviews 
see Annes et al., 2003; Hyytiäinen et al., 2004; Young and Murphy-
Ullrich, 2004; Fontana et al., 2005; Gomez-Duran et al., 2006). 
Autoantibodies to a fi  brillin-1 proline-rich region induce fi  bro-
blast activation possibly by releasing sequestered TGFβ1 from 
microfi  brils (Zhou et al., 2005). BMP-1 also controls TGFβ1 
activation by cleaving LTBP-1 (Ge and Greenspan, 2006). Once 
activated, TGFβ binding to TGFβRI and II heterodimers leads 
to the phosphorylation of TGFβRI, which, in turn, phosphory-
lates signaling proteins Smad2 and Smad3 (for reviews see Shi 
and Massague, 2003; Feng and Derynck, 2005). Smad2 and 
Smad3 phosphorylation allows association with Smad4, nuclear 
translocation, and specifi  c gene activation or repression.
We have discovered that in the presence of cells, a specifi  c 
fi  brillin-1 sequence encoded by exons 44–49 regulates the bio-
availability of endogenous TGFβ1, thereby stimulating Smad2 
signaling. Fibrillin-1–mediated TGFβ release from ECM does 
not require intact cells, proteolysis, or changes in the expression of 
TGFβ or its receptors. A fi  brillin-1 fragment containing the TGFβ-
regulating sequence specifi  cally binds deposited   fi  brillin-1 
in the insoluble cell layer through a strong interaction with the 
fi  brillin-1 N-terminal region. This interaction, which directly 
inhibits the association of C-terminal LTBP-1 with fi  brillin-1, 
can thus release LLC from microfi  brils. This novel mechanism 
is likely to contribute to TGFβ dysregulation in MFS and  related 
diseases and in acquired fi  brotic disorders.
Results
Regulation of TGF𝗃 signaling by a speciﬁ  c 
ﬁ  brillin-1 sequence
Our fi  rst step was to determine whether fi  brillin-1 could stimu-
late the Smad2 pathway. Recombinant fragments encompassing 
Figure 1.  Human recombinant ﬁ  brillin-1 fragments spanning full-length ﬁ  brillin-1. Fibrillin-1 fragments were cloned into pCEP-His, expressed in 293-EBNA 
cells, and puriﬁ  ed as previously described (Cain et al., 2005, 2006; Marson et al., 2005). The asterisk denotes the six cbEGF-like domains in fragments 
PF10 and PF11 that regulate TGFβ.
Figure 2.  PF10 and PF11 stimulate Smad2 phosphorylation. 0.15 μM of 
ﬁ  brillin-1 recombinant fragments PF1, PF2, PF8, PF9, PF10, PF11, PF12, 
PF13, PF14, and PF15 were tested for their ability to stimulate Smad2 
phosphorylation. The negative control (Con) contained no added proteins. 
4 nM of human recombinant TGFβ1, which stimulates Smad2 signaling, 
was a positive control. 0.15 μM of human plasma ﬁ  bronectin (FN) was an 
additional control. Only PF10 and PF11 stimulated Smad2 signaling. This 
experiment was repeated three times with similar results.FIBRILLIN-1 REGULATES TGFβ1 • CHAUDHRY ET AL. 357
full-length human fi  brillin-1 (Fig. 1) were tested for their ability 
to induce Smad2 phosphorylation in human dermal fi  broblasts 
(HDFs) that were cultured in serum-free conditions. Overlap-
ping fragments PF10 and PF11 but not overlapping fragments 
PF8, PF9, PF12, and PF14 were found to stimulate Smad2 
  signaling (Fig. 2). No other fi   brillin-1 fragments or human 
plasma fi  bronectin stimulated Smad2 phosphorylation (Fig. 2). 
Thus, the Smad2-stimulating effect was mapped to a specifi  c 
 fi brillin-1 sequence of six contiguous cbEGF-like domains that 
are encoded by exons 44–49 (Fig. 1, asterisk). Similar results 
were obtained using the mouse osteoblast cell line 2T3 (unpub-
lished data). ELISA assays revealed that purifi  ed PF10 alone 
contained no active TGFβ (R
2 0.9988), and repeated mass 
  spectrometry failed to detect any trace of LAP or TGFβ tryptic 
peptides in purifi  ed PF10 preparations (Cain et al., 2006; 
 unpublished  data).
Stimulation of Smad2 signaling by ﬁ  brillin-1 
requires TGF𝗃RI and II
TGFβ1 signals through a heteromeric complex of TGFβRI and 
II, which have serine/threonine kinase activity (for reviews see 
Shi and Massague, 2003; Feng and Derynck, 2005). We investi-
gated whether the Smad2 signaling effects of fi  brillin-1 fragments 
PF10 or PF11 were exerted through these receptors (Fig. 3). 
First, an antibody that blocks TGFβRII was used in cell signal-
ing inhibition assays. In the presence of the inhibitory TGFβRII 
antibody, there was no Smad2 stimulation by PF10 (Fig. 3 A) or 
PF11 (not depicted). The TGFβRII-inhibiting antibody also 
blocked TGFβ1-induced Smad2 phosphorylation (Fig. 3 A).
A chemical inhibitor, [3-(pyridin-2-yl)-4-(4-quinonyl)]-
1H-pyrazole, which is an ATP-competitive inhibitor of TGFβRI 
kinase (Sawyer et al., 2003), was then used in Smad2 signaling 
inhibition assays to ascertain whether TGFβRI was also involved 
Figure 3.  PF10 stimulates Smad2 phosphorylation through TGF𝗃Rs and activates TGF𝗃1. (A) When TGFβRII was blocked using 15 μg/ml of a neutral-
izing antibody (RII), Smad2 phosphorylation caused by PF10 stimulation was ablated (***, P < 0.0001 by t test in comparison with the PF10 control). 
A control antibody that has no inhibitory effect on the TGFβ pathway (IgG) conﬁ  rmed that ablation of PF10 stimulation was caused by the speciﬁ  c 
TGFβRII antibody. (B) PF10 stimulation of Smad2 signaling was ablated when TGFβRI was blocked using a TGFβRI kinase chemical inhibitor (RI; ***, 
P < 0.0001 by t test in comparison with the PF10 control). (A and B) Control samples (Con) contained no added proteins. The TGFβRII-inhibiting anti-
body (A) and TGFβRI kinase inhibitor (B) also blocked TGFβ1-activated Smad2 signaling (***, P < 0.0001 in comparison with the TGFβ1 control). 
(C) When active endogenous TGFβ1 was blocked using 15 μg/ml of a neutralizing antibody (β1), there was a marked reduction in PF10-induced 
Smad2 signaling (***, P < 0.0001 by t test in comparison with the PF10 control). In the presence of anti-TGFβ1 antibody, controls with added TGFβ1 
showed reduced activation of Smad2 (***, P < 0.0001 in comparison with the TGFβ1 control). A further control contained no added proteins. A con-
trol antibody that has no inhibitory effect on the TGFβ pathway (IgG) conﬁ  rmed that the effects were caused by the speciﬁ  c TGFβ1 antibody. (A–C) 
Quantitative analysis was performed by densitometry with data normalized against β-actin. Data are represented as the mean of three repeated experi-
ments. Error bars represent the SD of the three   experiments. (D) Endogenous TGFβ1 activity produced by stimulating cells for 90 min with PF10 
and PF11 at a concentration of 1 μM was assayed using the TGFβ1 EMax Immunoassay kit. The control that contained no added proteins and the 
  ﬁ  bronectin (FN) control showed no increase in active TGFβ1. (E) PF10 stimulated active and total TGFβ1 levels in cell layers and lysed cell layers. 
  ELISA assays revealed that when 1.5 μM PF10 was incubated in fresh serum-free medium with intact cell layers (90 min), high levels of total and 
active TGFβ1 activation occurred with a small but statistically signiﬁ  cant (*, P < 0.05 by protected t test) decrease in active TGFβ relative to total TGFβ. 
When PF10 was incubated with lysed cell layers (PF10 (L)), levels of total and active TGFβ were statistically similar, and, in both cases, 83% of levels 
using intact cell layers (***, P < 0.0001; active and total TGFβ in PF10 lysed cells   compared with PF10 in unlysed cells; two-way ANOVA followed 
by a posthoc Tukey’s test). The control that contains no added proteins and was subjected to cell lysis (Con (L)) shows a small but statistical increase in 
both active and total TGFβ when compared with the unlysed control (**, P < 0.001 by two-way ANOVA followed by a posthoc Tukey’s test). Thus, 
PF10 releases TGFβ mainly from the cell layer. (D and E) All experiments were performed in   triplicate and on the same microtitre plate (D, R
2 0.9989; 
E, R
2 0.9988). Error bars represent the SD of a single experiment that was undertaken in triplicate. The experiment was repeated at least three times 
with similar results.JCB • VOLUME 176 • NUMBER 3 • 2007  358
in the PF10-mediated stimulation of Smad2 signaling. No Smad2 
signal in response to PF10 (Fig. 3 B), PF11 (not   depicted), or 
TGFβ1 (Fig. 3 B) was detected when TGFβRI was neutralized 
by this inhibitor. Thus, PF10 and PF11 exert their effects on 
Smad2 signaling through TGFβRI and II.
Regulation of TGF𝗃1 by ﬁ  brillin-1 
fragments and molecules
Using an antibody that specifi  cally inhibits active TGFβ1, the 
Smad2 signal was markedly reduced upon stimulation with 
PF10 (Fig. 3 C) or PF11 (not depicted). In control experiments 
with supplemented TGFβ1, the inhibitory TGFβ1 antibody 
also blocked Smad2 phosphorylation (Fig. 3 C). Thus, Smad2 
phosphorylation by PF10 or PF11 requires active TGFβ1, and 
fi  brillin-1 does not directly activate these receptors.
Using ELISA assays, we found that the supplementation 
of HDF cultures with PF10 or PF11 increased active TGFβ1 in 
HDF serum-free medium (Fig. 3 D). After supplementing 1 μM 
HDF cultures for 90 min, PF10 treatment had enhanced active 
TGFβ1 to 23.7 pM and PF11 to 18.5 pM compared with me-
dium from untreated HDF cultures, which contained only trace 
levels of TGFβ1. Positive control experiments with added re-
combinant active TGFβ1 contained high levels of TGFβ1 as 
expected. Using human plasma fi  bronectin, there was no in-
crease in active TGFβ1 (R
2 0.9988; Fig. 3 D). PF10-treated cul-
tures had slightly more total than active TGFβ1 (Fig. 3 E).
PF10, which lacks the N-terminal three domains of PF11, 
also consistently generated a stronger Smad2 phosphorylation 
signal than PF11 at equal concentrations (0.15 μM; Fig. 4 A). 
However, both fragments showed a similar time-dependent 
Smad2 signaling response in which a marked increase in phos-
phorylated Smad2 from 5 to 20 min was seen with PF10 (Fig. 
4 B) and PF11 (not depicted).
The sequence within PF10 and PF11 that regulates 
 active  TGFβ1 levels and Smad2 signaling was localized to 
six cbEGF-like domains (Fig. 1, asterisk). We investigated 
whether its ability to enhance levels of active TGFβ was con-
formation dependent. After the preincubation of PF10 or PF11 
with the calcium chelator EDTA at a concentration of 100 mM, 
increased Smad2 phosphorylation was detected in the EDTA-
treated samples but not in the untreated or EDTA-only con-
trols (unpublished data). No EDTA-induced increase in Smad2 
phosphorylation was detected in control HDFs supplemented 
with TGFβ1 that had been preincubated with EDTA. PF10 
treatment with 0.2 mg/ml elastase, which degrades PF10 
(Fig. 4 C, i and ii), fi  brillin molecules, and microfi  brils (Kielty 
et al., 1994), also enhanced PF10-induced Smad2 signaling 
(Fig. 4 C, iii).
Full-length fibrillin-1 molecules that were purified 
from HDF culture medium stimulated Smad2 phosphoryla-
tion, but not as strongly as PF10 (Fig. 4 D). However, Smad2 
signaling activity was barely detectable after supplementing 
Figure 4. Efﬁ  cacies of different ﬁ  brillin-1 ligands in stimulating Smad2 phosphorylation. (A) The ability of PF10 and PF11 to stimulate Smad2 phosphorylation 
was compared at equal concentrations (0.15 μM). PF10 consistently generated a stronger signal than PF11. The control well (Con) contains no added pro-
teins. (B) Time course of PF10-induced Smad2 phosphorylation. 0.15 μM PF10 induced an increase in Smad2 phosphorylation within 10 min. (C) SDS-
PAGE analysis of 0.15 μM PF10 after treatment with 0.2 mg/ml porcine pancreatic elastase, a potent protease that degrades ﬁ  brillin-1 (Kielty et al., 
1994), showing the presence of degraded fragments. Lane M is a molecular marker lane; lane (i) is PF10; lane (ii) is PF10 after elastase treatment. Blots 
(iii) show the effects of PF10 with or without elastase treatment. After elastase, PF10 exhibited an enhanced ability to stimulate Smad2 signaling. The 
  control, which contained no added proteins, and 0.2 mg/ml of a further elastase-only control (El) did not induce Smad2 phosphorylation. The addition 
of 4 nM elastase to TGFβ1 did not increase Smad2 phosphorylation. (D) 0.15 μM of puriﬁ  ed full-length ﬁ  brillin-1 molecules (FBN-1) stimulated Smad2 
phosphorylation but weakly compared with 0.15 μM PF10. The control contains no added proteins. (E) TGFβ signaling activity was barely detectable after 
supplementing cultures with 0.15 μM microﬁ  brils (MF) puriﬁ  ed from bovine ciliary zonules. 0.15 μM of the PF10 control stimulated Smad2 phosphorylation 
as expected. The control contains no added proteins (Con). (A–E) Quantitative analysis was performed by densitometry with data normalized against 
β-  actin. Data are represented as the mean of three repeated experiments. Error bars represent the SD of the three experiments. ***, P < 0.0001 by t test 
in comparison with the PF10 control.FIBRILLIN-1 REGULATES TGFβ1 • CHAUDHRY ET AL. 359
cultures with microfi  brils purifi  ed from bovine ciliary zon-
ules (Fig. 4 E), possibly as a result of masking of the TGFβ 
regulatory sequence.
ELISA assays revealed that regulation of active TGFβ lev-
els by PF10 or PF11 or by fi  brillin molecules purifi  ed from HDF 
culture medium in the HDF cultures for 90 min was dose depen-
dent (0.0625–2 μM). Linear regression analysis showed that 
the slope of the regression line for PF10 was greater than PF11, 
although it was not statistically signifi  cant. However, PF10 did 
show a statistical increase in active TGFβ1 when compared with 
intact fi  brillin-1 molecules (R
2 0.9993; Fig. 5 A).
TSP-1 activates TGFβ1 by interacting with SLC (Young 
and Murphy-Ullrich, 2004). The active TGFβ1 sequence RKPK 
associates with the LAP sequence LSKL; SLC interactions with 
TSP-1 sequences KRFK and WSXW result in the release of 
 active  TGFβ1. These TSP-1 sequences are not present within 
PF10. A comparison of the effects of human TSP-1 and fi  brillin-1 
fragment PF10 on TGFβ1 showed that at equimolar concentrations 
(15 nM), PF10 treatment increased 1.1 pM of active TGFβ1 
more than TSP-1 (R
2 0.9989; Fig. 5 B).
Regulation of TGF𝗃 by ﬁ  brillin-1 requires 
cell layers but not intact cells
Having shown that PF10 treatment increases active TGFβ1 in HDF 
cultures supplemented with serum-free medium, we used ELISA 
assays to determine whether this effect requires intact cells, cell 
layer ECM, or HDF-conditioned medium. 1.5 μM PF10 strongly 
enhanced active TGFβ1 when incubated with cell layers in freshly 
added serum-free medium (Fig. 6). In contrast, when PF10 was 
added to conditioned medium alone, it induced a very small but 
signifi  cant increase in active TGFβ1 at 15 and 60 min (4–7% of 
active TGFβ1 levels induced by cell layers; R
2 0.9985; Fig. 6).
We also compared total and active TGFβ1 levels in cell 
layers before and after cell lysis (Fig. 3 E). PF10 treatment of 
lysed cell layers led to release into serum-free medium of 83% 
of the levels of both total and active TGFβ1 that were released 
using unlysed cultures (Fig. 3 E), with no statistical difference 
between active and total TGFβ1 levels released from the lysed 
cell layers. Thus, the deposited cell layer ECM is the main re-
quirement for the PF10-mediated increase in active TGFβ1.
Regulation of TGF𝗃 by ﬁ  brillin-1 does not 
require integrin or syndecan-4 receptors
The cell lysis experiments indicated that most of the TGFβ1 reg-
ulatory effect of PF10 resided within lysed cell layers. Neverthe-
less, we decided to further study whether cell surface receptors 
infl  uenced the PF10-mediated increase in Smad2 signaling because 
integrins have previously been implicated in TGFβ activation 
(Annes et al., 2004). The addition of integrin function–blocking 
antibodies to β1 or αv had no signifi  cant effect on PF10- or PF11-
mediated Smad2 signaling (Fig. 7 A). The blocking antibody 
(mAb 16) to α5 did have a small but signifi  cant enhancing effect 
on TGFβ activation (Fig. 7 A); an α5-integrin–blocking antibody 
Figure 5. Quantiﬁ  cation of active TGF𝗃1 after treatment with PF10, PF11, 
and TSP-1. (A) ELISA assays revealed that PF10, PF11, and ﬁ  brillin-1 mole-
cules showed dose-dependent increases (0.0625–2 μM) in active TGFβ1 
when HDF cells were stimulated for 90 min. A plot of the concentration of ac-
tive TGFβ1 (picomolar) against the concentration of protein (micromolar) is 
shown with a regression line for each protein. The table below shows the 
B value and the 95% conﬁ  dence interval (CI) for each protein. The slope of the 
regression line for PF10 is greater than that for PF11, although it is not statisti-
cally signiﬁ  cant. PF10 shows an increase in active TGFβ1 when compared 
with intact ﬁ  brillin-1 molecules (R
2 0.9993). The control contained no added 
proteins and showed no increase in active TGFβ1. All experiments were per-
formed in triplicate and on the same microtitre plate (R
2 0.9993). (B) Supple-
mentation with 15 nM PF10 induced 1.1 pM more active TGFβ1 than 15 nM 
TSP-1 (***, P < 0.0001 by t test in comparison with TSP-1; R
2 0.9989). The 
control, which contained medium only, and the ﬁ  bronectin (FN) control both 
showed no increase in active TGFβ1. All experiments were performed in 
triplicate and on the same microtitre plate (R
2 0.9989). Error bars represent 
the SD of a single experiment that was undertaken in triplicate. (A and B) The 
experiment was repeated at least three times with similar results.
Figure 6.  PF10-mediated increase in active TGF𝗃1 requires cell layers. 
Conditioned HDF medium that had been preincubated with HDF for 15 
min, 60 min, and 24 h was stimulated with 1.5 μM PF10. In the absence 
of cells, PF10 induced only very low but statistically signiﬁ  cant levels of ac-
tive TGFβ1 in the 15- (**, P < 0.001 by t test) and 60-min (***, P < 
0.0001 by t test) incubations compared with the controls. The conditioned 
medium control contains no PF10 and shows no active TGFβ1. The positive 
control contains 1.5 μM PF10 incubated in the presence of cells for 90 min 
and shows high levels of active TGFβ1. All experiments were performed in 
triplicate and on the same microtitre plate (R
2 0.9985). Error bars repre-
sent the SD of a single experiment that was undertaken in triplicate. The 
experiment was repeated at least three times with similar results.JCB • VOLUME 176 • NUMBER 3 • 2007  360
has previously been shown to activate TGFβ in cultures 
(Matsumoto et al., 2003). However, when HDFs were coincubated 
with PF10 in the presence of 1.5 mM EDTA, which chelates di-
valent cations and inhibits integrins (Mould et al., 1995), there was 
no effect on the PF10-mediated increase in Smad2 signaling (un-
published data). Syndecan-4–null mouse embryonic fi  broblasts 
signifi  cantly increased Smad2 signaling in response to PF10, as did 
the wild-type control fi  broblasts (Fig. 7 B). Thus, PF10-mediated 
TGFβ regulation occurs in the absence of syndecan-4.
Regulation of TGF𝗃 by ﬁ  brillin-1 does 
not involve proteolysis
Activation of TGFβ from the SLC complex can involve pericel-
lular proteolysis (for review see Munger et al., 1997). To inves-
tigate whether proteases are involved in the fi  brillin-1–mediated 
increase in Smad2 signaling, HDFs were preincubated for 30 
min with inhibitors of serine (aprotinin and leupeptin), cysteine 
(leupeptin), and/or metalloproteinases (4-Abz-Gly-Pro-d-Leu-
d-Ala-NH-OH). Quantitative analysis of densitometric data that 
was normalized against β-actin confi  rmed that none of these 
protease inhibitors had any substantial effect on PF10-stimulated 
Smad2 signaling (unpublished data).
Regulation of TGF𝗃 by ﬁ  brillin-1 does 
not involve rapid gene expression changes 
in TGF𝗃 or its receptors
PF10 and PF11 induction of TGFβ signaling could be caused 
by rapid changes in the gene expression of TGFβ and its 
 receptors. mRNA samples from HDFs supplemented for 30 min 
with PF10 or PF11, with TGFβ1 as a positive control, or with 
no ligand as a negative control were used in semiquantitative 
RT-PCR experiments. There were no detectable differences in 
the expression levels of TGFβ1 and TGFβRI/II/III during the 
time frame of fi  brillin-1–mediated enhanced TGFβ signaling 
(unpublished data).
Mechanism of TGF𝗃 regulation by ﬁ  brillin-1
PF10 binds full-length ﬁ  brillin-1 in the cell layer 
and medium. Affi  nity chromatography was used to isolate 
secreted molecules that specifi  cally interact with PF10 from 
collagenase extracts of HDF cell layers cultured in serum-free 
conditions. Using mass spectrometry analysis, full-length 
fi  brillin-1 was the only ECM molecule in the insoluble cell 
layer that was found to bind PF10 (Table I). [ID]TBL1[/ID] We detected 43 
fi  brillin-1 peptides, 23 of which were not present within the 
PF10 sequence itself. Similar results were observed when using 
HDF grown in medium supplemented with 10% serum. Thus, 
PF10 added in medium interacts specifi  cally with fi  brillin-1 in 
the insoluble cell layer.
PF10 binds the N-terminal region of 
ﬁ  brillin-1 (PF1). As we previously reported, it was not 
possible to coat BIAcore chips with the fi  brillin-1 fragments   
(Cain et al., 2005; Marson et al., 2005). However, solid-phase 
binding assays of overlapping fi  brillin-1 fragments (Fig. 1) 
revealed that PF10 strongly and specifically interacted 
with the N-terminal region of fi  brillin-1 (fragment PF1) with 
Figure 7.  Regulation of TGF𝗃1 by PF10 does not require cell surface receptors. (A) 20 μg/ml of integrin function–blocking antibodies to αv (17E6) and 
β1 (mAb 13) had no signiﬁ  cant inhibitory effect on the PF10-mediated stimulation of Smad2 signaling by 0.15 μM of ﬁ  brillin-1 fragment PF10. The α5-
blocking antibody (mAb 16) induced a small but signiﬁ  cant (*, P < 0.05 by t test) increase in Smad2 signaling. The control (Con), which contained no 
added proteins, and antibody controls (β1, αv, and α5 antibodies) showed no Smad2 phosphorylation. Active TGFβ1 was used as a positive control. 
(B) 0.15 μM PF10 was able to induce signiﬁ  cant stimulation of Smad2 signaling (***, P < 0.0001 by t test in comparison with the control) in a syndecan-4–
null mouse embryonic ﬁ  broblast culture, indicating that absence of the syndecan-4 receptor does not block PF10-mediated Smad2 signaling. Wild-type (wt) 
ﬁ  broblasts were used as a positive control (*, P < 0.05 by t test; PF10 in comparison with the control). A negative control contains no added proteins. 
4 nM TGFβ1 was an additional control for Smad2 signaling. (A and B) Quantitative analysis was performed by densitometry with data normalized against 
β-actin. Data are represented as the mean of three repeated experiments. Error bars represent the SD of the three experiments.FIBRILLIN-1 REGULATES TGFβ1 • CHAUDHRY ET AL. 361
relatively high affi  nity (dissociation constant [KD] = 90 ± 14 nM; 
Fig. 8 A). [ID]FIG8[/ID] Thus, this interaction mediates the association of 
PF10 with full-length fi  brillin-1.
We also examined the effects of two MFS disease– causing 
mutations in the N-terminal region (PF1) on interactions with 
PF10. Both MFS mutant forms of PF1 showed altered affi  nities 
for PF10. Mutant PF1
V449I exhibited increased affi  nity (KD = 
52 ± 13 nM), whereas mutant PF1
R62C bound very weakly. 
These altered affi  nities may affect PF10-stimulated Smad2 sig-
naling and possibly MFS phenotype.
Fibrillin-1 fragments PF10 and PF1 do not 
bind immobilized SLC. We found no evidence for direct 
SLC binding to fi  brillin-1 fragments PF10 or PF1 (unpublished 
data). Cross-linking of PF10 and SLC with bis[sulfosuccinimidyl] 
suberate was initially undertaken. However, no detectable band 
was identifi  ed that contained both PF10 and latent TGFβ1, as 
was previously shown for TSP-1 (Schultz-Cherry et al., 1994). 
A blot overlay assay with PF10 immobilized onto nitrocellulose 
and recombinant SLC added as a soluble ligand also failed to 
detect bound ligand. Furthermore, no interactions were found 
Figure 8.  PF10 interacts with the ﬁ  brillin-1 N-terminal region 
(PF1) and inhibits PF1 interaction with LTBP-1. (A) Solid-phase 
binding assays of 0–200 nM of soluble biotinylated PF10 to 200 
nM of immobilized ﬁ  brillin-1 fragments showed that PF10 inter-
acts speciﬁ  cally with the N-terminal region of ﬁ  brillin-1 (PF1) with 
moderately strong afﬁ  nity (KD = 90 ± 14 nM). Mutant PF1
V449I 
had increased afﬁ  nity (KD = 52 ± 13 nM), but mutant PF1
R62C 
bound very poorly. Nonspeciﬁ  c binding to BSA is shown. Results 
are presented as the mean ± SEM (error bars) of triplicate values. 
(B) Preincubation of 0.15 μM PF10 and PF1 for 15 min at 20°C 
caused a reduction in Smad2 signaling compared with the PF10-
only control (these data were normalized against corresponding 
β-actin; ***, P < 0.0001 by t test). Preincubation of PF10 with 
mutant PF1
V449I also reduced Smad2 signaling (***, P < 0.0001 
by t test in comparison with the PF10 control). However, there 
was no difference in Smad2 signaling after preincubation of 
PF10 and mutant PF1
R62C compared with the wild-type PF10 con-
trol experiment. The negative control (Con) contains no added 
proteins. Quantitative analysis was performed by densitometry 
with data normalized against β-actin. Data are represented as 
the mean of three repeated experiments. Error bars represent the 
SD of the three experiments (P < 0.05 by t test) in comparison 
with the PF10 control.
Table I. Mass spectrometry of HDF cell layer proteins that bound PF10
Protein identity Accession no. Mascot score Molecular mass No. of peptides
D
Fibrillin-1 precursor P35555 1335 332,682 43
Actin, cytoplasmic 1 P60709 227 42,052 8
Tubulin β-5 chain P05218 155 50,095 5
GAPDH P04406 120 36,070 3
Collagenase extraction of the HDF-insoluble cell layer was undertaken with subsequent PF10 afﬁ  nity chromatography. Mass spectrometry revealed that the only ECM 
molecule that PF10 bound in the insoluble cell layer was full-length ﬁ  brillin-1. We detected 43 ﬁ  brillin-1 peptides, 23 of which were not present within the PF10 se-
quence itself. The ﬁ  nal imidazole elution contained the ﬁ  brillin-1 fragment PF10, conﬁ  rming the afﬁ  nity protocol (unpublished data). The identiﬁ  ed proteins are shown 
in the order of Mascot score in the collagenase-extracted insoluble cell layer. The Mascot score is explained in Materials and methods. The samples were analyzed 
using a mass spectrometer (Micro-Q-TOF; Waters). The Mascot search engine (Matrix Science) and SwissProt database were used as previously described (Cain 
et al., 2006). The peptide and mass spectrometry/mass spectrometry tolerance were both ±0.3 D. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. GenBank/
EMBL/DDBJ accession numbers are given in the second column.JCB • VOLUME 176 • NUMBER 3 • 2007  362
using BIAcore, in which fi  brillin-1 fragments encompassing 
the entire molecule (200 nM) were passed over an SLC-
  immobilized chip. For these experiments, an antibody to latent 
TGFβ1 was used as a positive control. Recombinant MAGP-1, 
which binds the N-terminal fi  brillin-1 fragment PF1 (Rock 
et al., 2004), and fi  bronectin also did not bind SLC.
Preincubation of PF10 with PF1 blocks 
PF10-stimulated Smad2 signaling. When PF10 and 
PF1 were preincubated for 15 min at 20°C to allow association 
before supplementing HDF cultures, PF10-mediated Smad2 
signaling was signifi  cantly reduced compared with the PF10 
control (Fig. 8 B). Mutant PF1
V449I, which binds PF10 strongly, 
also reduced signaling. However, there was no difference in 
Smad2 signaling of mutant PF1
R62C, which binds PF10 weakly, 
compared with the PF10 control. These experiments show that 
the PF10–PF1 interaction is directly involved in increasing 
Smad2 signaling.
Preincubation of PF10 with PF1 inhibits 
the binding of LTBP-1 to PF1. An N-terminal 
fi  brillin-1 interaction with the C-terminal region of LTBP-1 has 
been predicted to stabilize LLC on microfi  brils (Isogai et al., 
2003; for review see Ramirez et al., 2004). Using BIAcore anal-
ysis, we fi  rst confi  rmed this N-terminal fi  brillin-1 (PF1) inter-
action with the C-terminal region of LTBP-1 (Fig. 9 A, i). [ID]FIG9[/ID ] The 
KD for this PF1–LTBP-1 interaction was 43.1 ± 5.9 nM. Subse-
quent BIAcore experiments confi  rmed that PF10 did not bind 
LTBP-1 (Fig. 9 A, ii) and revealed that preincubation of PF1 
with increasing concentrations of PF10 specifi  cally inhibited 
the PF1–LTBP-1 interaction (Fig. 9 A, iii). The IC50 for this 
PF10 inhibition was 2.42 ± 0.5 μM. Thus, PF10 can regulate 
TGFβ1 bioavailability by displacing LTBP-1 from fi  brillin-1 
and displacing LLC from microfi  brils.
PF10 fails to stimulate Smad2 signaling in 
the absence of microﬁ  brils. Using the rat UMR-106 
cell line that does not constitutively express or deposit fi  brillin-1 
or LTBP-1 (Dallas et al., 2000), PF10 had no signifi  cant effect 
on Smad2 signaling (Fig. 9 B). This result supports the require-
ment for fi  brillin microfi  brils and LTBP-1 in PF10-stimulated 
Smad2 signaling.
Discussion
Recent studies have shown that a major functional relationship 
exists between fi  brillin-1 and TGFβ activity (for reviews see 
Ramirez et al., 2004; Dietz et al., 2005). Fibrillin-1 is postulated 
to regulate TGFβ through the association of LLC with fi  brillin-
rich microfi  brils, although it is not clear how this regulation 
occurs. We have discovered that a specifi  c fi  brillin-1 sequence 
encoded by exons 44–49 (in recombinant fragments PF10 and 
PF11) enhances endogenous active TGFβ1 and Smad2 signal-
ing. This sequence, which is present within a pepsin-resistant 
microfi  bril proteolytic fragment (Maslen et al., 1991), contains 
no TB motif such as those in LTBP-1 and -3 that bind LAP 
through disulphide linkage (for review see Hyytiäinen et al., 
2004). Thus, fi   brillin-1 enhances active TGFβ1 by a novel 
mechanism and may contribute directly to the lung, skeletal, 
and vascular pathologies of MFS and related diseases.
We excluded the idea that purifi  ed PF10 or PF11 con-
tained traces of latent or active TGFβ by mass spectrometry and 
immunoblotting, and we did not detect any TGFβ1 activity in 
our purifi  ed PF10 or PF11 preparations. The smaller fi  brillin-1 
sequences tested had greater ability to stimulate Smad2 signal-
ing. PF10 induced slightly greater levels of active TGFβ and 
Smad2 signaling than PF11, which comprises PF10 plus three 
additional upstream domains, and both fragments induced 
greater levels of active TGFβ and Smad2 signaling than intact 
fi  brillin. Small-angle x-ray analysis and single-particle trans-
mission electron microscopy of the solution structure of fi  brillin-1 
recently revealed that the region spanning TB4 to TB6 (PF11) 
is relatively compact, with PF10 being the most linear region 
within PF11 (Baldock et al., 2006). The additional three- domain 
globular region of PF11 and other domains in full-length fi  brillin-1 
may exert conformational effects that reduce the availability of 
the sequence encoded by exons 44–49. We previously showed 
Figure 9.  PF10 inhibits the binding of PF1 and CT LTBP-1, and PF10 does 
not activate TGF𝗃1 in UMR-106 cells. (A) BIAcore analysis of the interac-
tion of C-terminal LTBP-1 with the ﬁ  brillin-1 N-terminal fragment PF1 as well 
as inhibition by PF10. Fibrillin-1 protein fragments PF1 (i) or PF10 (ii) were 
injected over LTBP-1 immobilized using amine coupling on a CM5 sensor 
chip. Both sensorgrams show analyte concentrations ranging from 0 to 
150 nM, and duplicate concentrations were included in every run. One 
representative experiment is shown in each case. Only PF1 interacted with 
LTBP-1. Response difference is the difference between experimental and 
control ﬂ  ow cells in response units. Time is shown in seconds. Inhibition of 
the maximum response of 50 nM PF1 to LTBP-1 is shown in panel iii. In-
creasing concentrations of PF10 (0–30 μM) was incubated with PF1 be-
fore addition to immobilized LTBP-1. PF10 inhibited PF1 binding to LTBP-1 
(IC50 = 2.42 ± 0.5 μM). (B) Densitometry analysis of Smad2 phosphoryla-
tion by UMR-106 cells revealed that treatment with PF10 failed to induce 
Smad2 signaling when compared with the control. The addition of active 
TGFβ1 was a positive control. No added protein was a negative control 
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that elastase effectively degrades microfi   brils and fi  brillin 
molecules (Kielty et al., 1994), and, here, we have found that 
the elastase degradation of PF10 enhances Smad2 signaling. 
In tissues, such proteolytic fragments may potently stimulate 
TGFβ-induced signaling. We found only trace levels of 
Smad2 signaling induced by tissue-purifi  ed microfi  brils. The 
active PF10 sequence may be masked by molecular folding 
and/or by associated molecules. We previously mapped this 
fibrillin-1 region to the microfibril interbead (Baldock 
et al., 2001).
TSP-1 has previously been identifi  ed as a physiological 
activator of TGFβ (Schultz-Cherry et al., 1994). ELISA dose-
response curves have revealed that PF10 was more effective at 
activating endogenous TGFβ1 than TSP-1. The active TGFβ 
sequence RKPK associates with the LAP sequence LSKL in the 
SLC (Young and Murphy-Ullrich, 2004); the TSP-1 activation 
of TGFβ involves competitive binding of a TSP-1 sequence 
(KRFK) that releases TGFβ from SLC. Sequence analysis of 
the six cbEGF domains in PF10 that regulate TGFβ bioavail-
ability revealed no similar motifs, so PF10-mediated TGFβ1 
activation involves a different mechanism.
Latent TGFβ can also be activated by integrin αvβ6 or 
proteolysis (Annes et al., 2004; Fontana et al., 2005). However, 
PF10-mediated regulation of TGFβ1 did not involve cell sur-
face β1- or αv-integrin receptors, syndecan-4, or pericellular 
proteolysis. Moreover, changes in TGFβ-induced signaling 
could not be accounted for by the enhanced expression of TGFβ 
or its receptors.
To determine how fi  brillin-1 enhances active TGFβ and 
stimulates Smad2 signaling, we fi  rst investigated what PF10 
interacts with in HDF cultures. Mass spectrometry revealed 
that PF10 bound specifi  cally to full-length fi  brillin-1 in the 
 microfi  bril-rich insoluble fi  broblast layer, which is a proposed re-
pository of LLC (for review see Ramirez et al., 2004), and also 
bound with high affi  nity to the N-terminal fi  brillin-1 fragment 
PF1 in solid-phase binding assays. The PF1 sequence localizes 
adjacent to microfi  bril beads (Reinhardt et al., 1996; Baldock 
et al., 2001). We found no evidence for SLC interactions with 
either PF10 or PF1 or for LTBPs interacting directly with PF10. 
Crucially, however, preformed PF10–PF1 complexes reduced 
PF10-induced Smad2 signaling, confi  rming a key role for this 
interaction in regulating active TGFβ1. Moreover, MFS mutant 
PF1 fragments that had increased or decreased affi  nity for PF10 
showed reduced or unchanged Smad2 signaling, respectively. 
Next, we showed that the PF10 interaction with PF1 directly in-
hibits C-terminal LTBP-1 binding to the fi  brillin-1 N terminus 
so that, at appropriate concentrations, it will displace LLC from 
microfi  brils. Finally, we confi  rmed that PF10 has no effect on 
Smad2 signaling in UMR-106 cell cultures, which do not con-
stitutively express fi  brillin-1 or LTBP-1 (Dallas et al., 2000). 
Thus, we have delineated a novel mechanism that regulates 
TGFβ bioavailability (Fig. 10) in which PF10, by binding micro-
fi  brils close to the beads through interactions with the fi  brillin-1 
N-terminal sequence, can displace LTBP-1 and LLC from 
microfi  brils. One possible mechanism of subsequent TGFβ acti-
vation may be the BMP-1 cleavage of LTBP-1 (Ge and Greenspan, 
2006). Alternatively, TGFβ may become activated during the 
release of LLC from microfi   brils through conformational 
changes because fi  brillin-1– and SLC-binding sites are within 
the same C-terminal region of LTBP-1. The LTBP-1 N terminus 
can be transglutaminase linked to ECM (for review see Rifkin, 
2005), but release of the LTBP-1 C terminus from microfi  brils 
may be suffi  cient for TGFβ activation.
Further experiments confi  rmed that PF10 releases TGFβ1 
mainly from lysed cell layers as expected because fi  brillin-1 is 
a major deposited ECM component. The small increase in 
TGFβ1 levels when cells are intact may be caused by additional 
microfi  brils assembling at the cell surface. Low levels of active 
TGFβ1 released by PF10 from conditioned medium probably 
refl  ect the known presence of some secreted fi  brillin-1 mole-
cules and aggregates in medium (Reinhardt et al., 2000a; un-
published data).
Enhanced PF10-mediated Smad2 signaling after EDTA 
treatment indicates that calcium-dependent conformation of 
the cbEGF-like domain array infl  uences activation, perhaps by 
altering the PF1–PF10 interaction. We have also found that 
  supplementing cultures with heparin enhances PF10-dependent 
TGFβ activation, but we have excluded that this heparin effect 
is caused by direct heparin–PF10 interactions (unpublished 
data). Heparin strongly binds PF1 in a conformation-dependent 
Figure 10.  Model of how PF10 regulates TGF𝗃 bio-
availability. Secreted LLC becomes associated with 
  deposited ﬁ  brillin microﬁ  brils (LTBP-1, a component of 
LLC, is shown in red). The PF10 fragment (orange), 
which is released by proteolysis, binds microﬁ  brillar 
ﬁ  brillin-1 within the insoluble cell layer, interacting 
  speciﬁ  cally with the ﬁ  brillin-1 N-terminal region (PF1; 
blue). PF10 binds assembled microﬁ  brils at or adja-
cent to the beads where this N-terminal region local-
izes (Reinhardt et al., 1996; Baldock et al., 2001). 
PF10 inhibits the PF1 interaction with LTBP-1 (and thus 
with LLC), leading to the release of LLC and an increase 
in active TGFβ. Microﬁ   bril beads (gray ovals) and 
interbead regions (lines between ovals) are indicated.JCB • VOLUME 176 • NUMBER 3 • 2007  364
manner (Cain et al., 2005; unpublished data), so we speculate 
that it may enhance LTBP-1 displacement from PF1 by PF10.
Pathological fi  brillin-1–mediated regulation of TGFβ bio-
availability may be induced by microfi  bril degradation products. 
Progressive proteolytic damage and aortic degeneration are 
hallmarks of classic MFS. Disease-causing amino acid substitu-
tions are spread throughout the molecule (for review see Robinson 
et al., 2006), but some mutations occur within PF10 that may 
directly alter TGFβ activation. They include classic MFS caus-
ing amino acid substitutions in exons 44 and 46, exon 47/48 
  domain interface, exons 47 and 48, and deletions of exons 44, 
44–46, 46, and 49 (www.umd.be). Furthermore, mutations in 
any region of fi  brillin-1 that disrupt domain and molecular con-
formations can increase proteolytic susceptibility to infl  amma-
tory enzymes (Ashworth et al., 1999; Booms et al., 2000; 
Reinhardt et al., 2000b; Suk et al., 2004; Vollbrandt et al., 2004), 
leading to microfi  bril proteolysis and release of TGFβ-regulating 
fragments. Microfi  brils from unaffected individuals are also 
highly susceptible to degradation by matrix proteases such as 
elastase (Ashworth et al., 1999). Thus, microfi  bril proteolysis 
could be a common mechanism for the release of active TGFβ1 
from ECM in heritable and acquired fi  brillinopathies. In sum-
mary, we have shown that a specifi  c fi  brillin-1 sequence regu-
lates the bioavailability of TGFβ1. We are currently investigating 
whether fi  brillin-1 similarly regulates levels of other TGFβ iso-
forms and whether other fi  brillins can regulate TGFβ.
Materials and methods
Cell cultures
Tissue culture reagents were purchased from Life Technologies or Mediat-
ech. 293-EBNA cells were purchased from the American Type Tissue Cul-
ture Collection and were routinely maintained in DME with 10% FBS, 
2 mM L-glutamine, 100 U/ml penicillin/streptomycin, and 250 μg/ml 
G418. HDFs were purchased from Cascade Biologics, Inc. and main-
tained in low serum growth supplement from the same supplier. UMR-106 
rat osteosarcoma cells were originally obtained from T.J. Martin (St Vincent 
Institute of Medical Research, Fitzroy, Victoria, Australia). 2T3 cells were a 
gift from S. Harris (University of Texas Health Science Center, San Antonio, 
TX; Ghosh-Choudhury et al., 1996).
Expression and puriﬁ  cation of recombinant ﬁ  brillin-1
Recombinant ﬁ  brillin-1 fragments encompassing full-length human ﬁ  brillin-1 
were expressed in 293-EBNA cells using a modiﬁ   ed pCEP-His vector 
and were puriﬁ   ed as previously described (Fig. 1; Cain et al., 2005; 
Marson et al., 2005). Secreted ﬁ  brillin molecules and multimers were puri-
ﬁ  ed from conﬂ  uent HDF culture medium by cesium chloride density gradi-
ent centrifugation and size fractionation using a Sephacryl 200 column 
equilibrated in 0.1 M NaCl, 1 mM CaCl2, and 50 mM Tris, pH 8.0. Iden-
tity and purity were conﬁ  rmed by immunoblotting using an anti–ﬁ  brillin-1 
mAb raised to the N terminus (amino acids 45–450; mAb 2502; Chemi-
con Europe) and by mass spectrometry (provided by B. Raynal, University 
of Manchester, Manchester, UK). Microﬁ  brils were puriﬁ  ed from adult bo-
vine ciliary zonules as previously described (Kielty et al., 1998). The pres-
ence of microﬁ  brils was conﬁ  rmed using atomic force microscopy (Sherratt 
et al., 2004).
Expression and puriﬁ  cation of recombinant C-terminal LTBP-1
A C-terminal fragment of human LTBP-1 (amino acids 1,008–1,394) 
was generated by PCR ampliﬁ  cation using Vent DNA polymerase (New 
England Biolabs, Inc.), a high ﬁ   delity DNA polymerase, according to 
the manufacturer’s instructions. The template was human LTBP-1 cDNA in 
the vector pSV7d (a gift from K. Miyazono, University of Tokyo, Tokyo, 
Japan). A 10-histidine epitope tag was engineered into the primers at 
the C terminus of the recombinant LTBP-1 fragments. The PCR products 
were ligated into pCEP-Pu expression vector (a gift from E. Kohfeldt, Max 
Planck Institute of Biochemistry, Martinsried, Germany) in frame with the 
BM40 signal sequence. Insert sequences were conﬁ  rmed by automated 
sequencing (MWG). Constructs were transfected into 293-BNA cells us-
ing LipofectAMINE 2000 (Invitrogen). Transfected cells were selected in 
1 μg/ml puromycin, and resistant cells were expanded into triple-layer 
ﬂ  asks. Recombinant fragments were puriﬁ  ed using a nickel-NTA agarose 
column (QIAGEN) according to the manufacturer’s instructions. Bound pro-
tein was eluted with low pH or with 100–300 mM imidazole. The protein 
was further puriﬁ  ed using a mono-Q ion exchange column in conjunction 
with a protein puriﬁ   cation system (BioCad 700E; Applied Biosystems). 
Bound protein was eluted with a linear 0–1-M NaCl gradient. Coomassie 
blue staining was used to visualize the purity of the fragment, and mass 
spectrometry/peptide mass mapping was used to validate the recombinant 
LTBP-1 fragment.
Smad2 signaling assays
Conﬂ  uent HDFs were incubated for 24 h using serum-free DME supple-
mented with 4.5 g/L glucose and L-glutamine (Cascade Biologics, Inc.). 
The cells were incubated in 0.5 ml of fresh serum-free DME containing 
0.15 μM of recombinant ﬁ  brillin-1 fragments, 0.15 μM of medium-puriﬁ  ed 
ﬁ  brillin-1 molecules, or 0.15 μM of tissue-puriﬁ  ed microﬁ  brils for 15 min 
at 37°C. 4 nM of recombinant human TGFβ1 (Sigma-Aldrich) was used as 
a positive control. Human plasma ﬁ  bronectin was used as an additional 
control (FC010; Chemicon Europe). Cells were washed twice with PBS, 
  incubated with NET buffer supplemented with fresh proteinase inhibitors 
(20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 2.5 mM EDTA, 100 
μM Na3VO4, 1% aprotinin, 1 mM PMSF, and 1% leupeptin) for 30 min, 
and scraped from the tissue culture ﬂ   ask. Cell lysates were electropho-
resed, and Western blots were undertaken using a Smad 2 antibody 
(AB3849; Chemicon Europe). Western blots were developed using electro-
chemiluminescence (GE Healthcare). Mr ﬁ  lm (BioMax; Kodak) was used 
to visualize positive bands. Each Western blot was stripped after use and 
reprobed with β-actin to ensure equal loadings of total protein (AC-15; 
Sigma-Aldrich). In some experiments, the effects of pretreating ﬁ  brillin-1 
fragments with EDTA, elastase, or heparin were determined. Protein frag-
ments were preincubated with 100 mM EDTA, pH 7.4, 100 μg/ml hepa-
rin (3,000 kD; Sigma-Aldrich), or 0.2 mg/ml porcine pancreatic elastase 
(Sigma-Aldrich) for 15 min before SDS-PAGE and Western blot analysis of 
Smad2 signaling. Signaling assays were also performed using the mouse 
osteoblast cell line 2T3 (Ghosh-Choudhury et al., 1996), syndecan-4–null 
and wild-type mouse embryonic ﬁ   broblast cell lines (gift from M.J. 
Humphries, University of Manchester, Manchester, UK), and UMR-106 
rat osteosarcoma cells (gift from T.J. Martin). Quantitative analysis was 
performed by densitometry with data normalized against β-actin. The den-
sitometry values are plotted as a ratio of Smad2 signaling against corre-
sponding β-actin. Data are represented as the mean of three repeated 
experiments and were statistically analyzed using unpaired t tests (Prism 
2.0 software; GraphPad). Error bars represent the SD of the three ex-
periments. Results are statistically signiﬁ  cant when the p-value is <0.05 
(*, P < 0.05; **, P < 0.001; ***, P < 0.0001).
Smad2 signaling inhibition assays
HDFs were incubated with inhibitory antibodies or chemical inhibitors for 
30 min at 37°C in 0.5 ml of serum-free DME before lysis and signaling as-
says (as described in the previous section). An anti-TGFβ1 mAb (mAb 240; 
R&D Systems) and an anti–human TGFβRII antibody (AF-241-NA; R&D 
Systems), which was designated RII in Fig. 3 A, were used at concentra-
tions of 15 μg/ml. A chemical inhibitor of TGFβRI, [3-(pyridin-2-yl)-4-
(4-quinonyl)]-1H-pyrazole (Merck Biosciences), which is designated as RI in 
Fig. 3 B, was used at a concentration of 20 μg/ml. The inhibitory integrin 
antibodies αv (17E6; Merck Biosciences), α5 (mAb 16), and β1 (mAb 13; 
gifts from M.J. Humphries) were used at concentrations of 20 μg/ml. 
Freshly prepared protease inhibitors were used at neutral pH at the follow-
ing concentrations: aprotinin (serine) at 100 μM, leupeptin (cysteine; 
Sigma-Aldrich) at 100 μM, and a matrix metalloproteinase inhibitor 
(4-Abz-Gly-Pro-D-Leu-D-Ala-NH-OH; inhibits matrix metalloproteinases 1, 3, 8, 
and 9; Merck Biosciences) at 150 μM. Quantitative analysis was per-
formed by densitometry with data normalized against β-actin. The densi-
tometry values are plotted as a ratio of Smad2 signaling against 
corresponding β-actin.
ELISA assays for active and total TGF𝗃1
The amounts of active TGFβ1 present in HDF medium were determined 
using the TGFβ1 EMax Immunoassay kit (Promega). Recombinant frag-
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37°C. The media were collected, and 200 μl was used in the EMax im-
munoassay, which was performed according to the manufacturer’s instruc-
tions. For measurement of total (active + latent) TGF, the samples were 
acidiﬁ   ed using HCl and were reneutralized before measurement using 
NaOH according to the ELISA manufacturer’s instructions (Promega; Dallas 
et al., 2005). TGFβ standard curves were undertaken for every assay. 
The standard curve is linear between 15.6 and 1,000 pg/ml of the 
TGFβ1 standard. All experiments were performed in triplicate and on the 
same microtitre plate. The data are represented as the mean values of one 
experiment. In some cases, other statistical methods were used: linear re-
gression analysis was undertaken using SPSS 12.0 software (SPSS), and 
two-way analysis of variance (ANOVA) was performed followed by a 
posthoc multiple comparisons test using Tukey’s test (SPSS 12.0 software). 
Furthermore, a protected two-tailed t test was performed in conjunction 
with ANOVA in some cases.
Semiquantitative RT-PCR
Recombinant proteins were added to HDFs in 0.5 ml of serum-free DME 
for 90 min at 37°C. Total RNA was isolated using the SV Total RNA Isola-
tion kit (Promega). RNA was quantitated using an RNA/DNA calculator 
(GeneQuant Pro; GE Healthcare). cDNA was synthesized from the extracted 
RNA using RT-PCR, and the products were resolved using 2.5% ultrapure 
agarose gels (Invitrogen). Oligonucleotide primers for PCR were designed 
using Primer3 software.
Afﬁ  nity chromatography and mass spectrometry
0.5 mg of the ﬁ  brillin-1 fragment PF10 was bound to a nickel chelate afﬁ  n-
ity chromatography column using a chromatography system (AKTAprime; 
GE Healthcare). HDF cell layers that had been lysed with NET buffer con-
taining fresh protease inhibitors (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 
1% NP-40, 2.5 mM EDTA, 100 μM Na3VO4, 1% aprotinin, 1 mM PMSF, 
and 1% leupeptin) were passed over the column followed by a wash using 
150 mM NaCl, 50 mM Tris-HCl, and 1 mM CaCl2, pH 7.4. The bound 
proteins were subsequently eluted using a gradient of 1 M NaCl, 50 mM 
Tris-HCl, and 1 mM CaCl2, pH 7.4. The procedure was repeated using the 
insoluble cell layer after treatment with 0.5 mg/ml collagenase in the pres-
ence of protease inhibitors (2 mM PMSF and 5 mM N-ethylmaleimide) in 
150 mM NaCl, 50 mM Tris-HCl, and 1 mM CaCl2, pH 7.4, for 24 h. After 
eluting bound molecules, the afﬁ  nity column was subjected to a ﬁ  nal elu-
tion step using 500 mM imidazole, 150 mM NaCl, 50 mM Tris-HCl, pH 
7.4, and 0.5 mM CaCl2. All fractions were desalted using a HiTrap desalt-
ing column (GE Healthcare). All samples were reduced and alkylated as 
previously described (Cain et al., 2006). To identify proteins bound to 
PF10, samples were analyzed using a mass spectrometer (Micro-Q-TOF; 
Waters) and the Mascot search engine (Matrix Science). The Mascot pro-
tein score is derived from the sum of the ion scores for each peptide de-
tected from that protein. The ion score of a peptide, which reﬂ  ects  the 
probability of the observed peptide mass matching the mass of the peptide 
in the database, is expressed as a value, log10(P), where P is the probabil-
ity (Perkins et al., 1999). The SwissProt database was used. Peptide toler-
ance and mass spectrometry/mass spectrometry tolerance were set to 
±0.3 D. In the ﬁ  nal imidazole elution, PF10 was the only ECM sequence, 
which conﬁ  rmed the afﬁ  nity protocol.
Solid-phase binding
Solid-phase binding was performed as previously described (Marson 
et al., 2005). In brief, 0–200 nM of soluble ligands were biotinylated, and 
ﬂ  at-bottomed microtitre plates (Thermo Labsystems) were coated with the 
N-terminal ﬁ  brillin-1 fragment (PF1) at 200 nM in TBS (50 mM Tris-HCl, 
pH 7.4, and 0.1 M NaCl) overnight at 4°C. BSA blocking, washing, binding, 
and detection steps were subsequently performed. Soluble biotinylated 
protein dilutions of 0–200 nM for binding curves were used. All assays 
were performed in triplicate and were repeated at least twice to conﬁ  rm 
the observed results. KD values for dose-dependent interactions were calcu-
lated using nonlinear regression with one-site binding (hyperbola). All data 
are shown as mean values ± SEM.
Chemical cross-linking
1  μg of the ﬁ   brillin-1 fragment PF10 was incubated with 1 μg of 
  recombinant latent TGFβ1 for 2 h at 37°C. The cross-linking agent BS
3 
(bis[sulfosuccinimidyl] suberate; Pierce Chemical Co.) was added at a 
  concentration of 0.25 mM and incubated for 15 min at 4°C. The proteins 
were electrophoresed, and potential bands of interest were analyzed using 
mass spectrometry as outlined above (see Afﬁ   nity chromatography and 
mass spectrometry).
Blot overlay assay
Blot overlays were performed essentially as previously described (Isogai 
et al., 2003). 25 μg of the ﬁ  brillin-1 fragment PF10 was electrophoresed 
using SDS-PAGE and was transferred onto nitrocellulose as described in the 
Smad2 signaling assays section. The membranes were blocked and incu-
bated with 50 μg/ml of latent TGFβ1 (299-LT/CF; R&D Systems) at 4°C 
overnight. A primary antibody to latent TGFβ1 (AF-246-NA; R&D Systems) 
followed by an enzyme-conjugated secondary antibody was used to detect 
bound ligand. Blots were developed using enhanced chemiluminescence 
as described in the Smad2 signaling assays section.
BIAcore 3000 analysis
Kinetic binding analysis of latent TGFβ1 with ﬁ  brillin-1 was undertaken by 
surface plasmon resonance using a biosensor (BIAcore 3000; BIAcore). To 
investigate possible interactions between ﬁ  brillin-1 and the SLC, 1.8 μg/ml 
of latent TGFβ1 (299-LT/CF; R&D Systems) was immobilized onto a CM5 
sensor chip in 10 mM acetic acid, pH 5.5. All subsequent binding experi-
ments were performed in 10 mM Hepes, pH 7.4, 0.1 M NaCl, 1 mM CaCl2, 
and 0.005% surfactant P20. 200 nM of ﬁ  brillin-1 fragments were applied to 
the sensor chip at a ﬂ  ow rate of 30 μl/min for 3 min. After 2.5-min dissocia-
tion, the chip was regenerated using 50 mM acetic acid for 30 s. The re-
sponse value for each injection was calculated using the binding assay result 
wizard (BIAcore control software 3.2; BIAcore). As a positive control, an SLC 
antibody (AF-246-NA; R&D Systems) was passed over the chip.
To analyze the binding of ﬁ  brillin-1 fragments to LTBP-1, a C-terminal 
fragment of LTBP-1 (designated CT LTBP-1; residues 1,008–1,394) was im-
mobilized onto a CM5 sensor chip at 25 μg/ml in 50 mM sodium acetate, 
pH 5.2. 0–150 nM of the ﬁ  brillin-1 fragments PF1 and PF10 were applied 
to the sensor chip (15 μl/min) for 6 min and were left to dissociate for 10 
min. Regeneration was performed in 10 mM Hepes, pH 7.4, 0.4 M NaCl, 
1 mM CaCl2, and 0.005% surfactant P20. The KD for the PF1 interaction 
was calculated by plotting a saturation binding curve using the equilibrium 
response value at the top of the curve as described previously (Cain et al., 
2005). The PF1 interaction was performed three times, and the ﬁ  nal KD 
was calculated from a mean of these values.
Increasing concentrations of PF10 (0–30 μM) were preincubated 
with 50 nM PF1 for 15 min before being applied to the sensor chip for 
3 min (30 μl/min) and were left to dissociate for 10 min. CT LTBP-1 on the 
sensor surface was then regenerated. The maximum response was plotted 
against concentration using Prism 2.0 software (GraphPad). No binding 
response occurred between PF10 and CT LTBP-1, so it was possible to de-
termine whether PF10 inhibits the interaction between PF1 and CT LTBP-1. 
The IC50 was calculated using nonlinear regression analysis (sigmoidal 
dose response; variable slope).
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